Does Emgality Cause Weight Gain?
Emgality (galcanezumab), a CGRP monoclonal antibody for migraine prevention, lists weight gain as an infrequent side effect in its prescribing information. Clinical trials reported it in less than 1% of patients, with no causal link established beyond coincidence. Real-world patient reports on forums and post-marketing data show some users experiencing modest weight gain (2-10 lbs over months), often tied to reduced migraine frequency allowing better appetite or less nausea, rather than direct drug effect.[1][2]
How Common Is Weight Gain on Emgality?
In pivotal trials (e.g., EVOLVE-1 and EVOLVE-2), weight increased by ≥7% in 0.7-1.3% of Emgality users versus 0.5-1.1% on placebo. No dose-response pattern emerged. FDA adverse event reporting (FAERS) through 2023 logs over 200 weight gain cases among ~500,000 prescriptions, but underreporting and confounding factors (e.g., lifestyle, comorbidities) limit interpretation. Most cases are mild and resolve after discontinuation.[3][4]
Why Might Some Patients Gain Weight?
Possible mechanisms include:
- Migraine relief improving eating habits or activity tolerance.
- Rare metabolic shifts from CGRP blockade, though animal studies show no direct adiposity effects.
- Interactions with antidepressants or steroids, common in migraineurs.
Patient reviews on Drugs.com (average 7.2/10 rating) note ~5-10% mentioning gain, often early in treatment.[2][5]
Does Emgality Cause Weight Loss Instead?
About 1-2% of trial patients lost ≥7% body weight, similar to placebo. Some users report loss due to nausea (3-5% incidence) or sustained migraine benefits enabling exercise. Net effect is weight-neutral for most.[1][3]
Compared to Other Migraine Preventives
| Drug | Weight Gain Risk | Notes |
|------|------------------|-------|
| Emgality | Low (<1%) | Neutral profile |
| Aimovig (erenumab) | Low (1-2%) | Similar CGRP class |
| Nurtec ODT (rimegepant, acute) | Minimal | Less data |
| Topamax (topiramate) | Loss (common) | Preferred for overweight patients |
| Beta-blockers (e.g., propranolol) | Gain (5-10%) | Metabolic slowdown |
Emgality has one of the lowest rates among injectables.[1][6]
What Do Patients Say and What Should You Watch For?
Reddit and WebMD threads highlight variable experiences: some gain despite diet control, others lose. Monitor weight monthly; consult a doctor if >5% change. No black-box warnings, but Eli Lilly advises reporting to FDA MedWatch. Alternatives like Ajovy may suit if concerned.[2][5]
[1] Emgality Prescribing Information (FDA.gov)
[2] Drugs.com - Emgality Reviews
[3] FAERS Public Dashboard (FDA.gov)
[4] ClinicalTrials.gov - EVOLVE Studies
[5] WebMD - Emgality Patient Forum
[6] Aimovig Prescribing Information (FDA.gov)